Jushi Holdings (JUSHF) Asset Writedowns and Impairment (2022 - 2023)
Jushi Holdings' (JUSHF) quarterly Asset Writedowns and Impairment came in at $8.6 million in Q4 2023, up 130.42% year-on-year from $3.7 million in Q4 2022, and up 130.42% on a QoQ basis from -$28.2 million in Q4 2022.
Jushi Holdings (JUSHF) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Jushi Holdings (JUSHF) has 2 years of Asset Writedowns and Impairment data on file, last reported at $8.6 million in Q4 2023.
- On a quarterly basis, Asset Writedowns and Impairment rose 130.42% year-over-year to $8.6 million in Q4 2023; TTM through Dec 2023 was $18.0 million, a 91.04% increase from a year earlier, with the FY2024 full-year figure at $432000.0, down 94.96% from the prior year.
- Asset Writedowns and Impairment for Q4 2023 stood at $8.6 million, up from -$28.2 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for JUSHF reached as high as $37.6 million in Q3 2022 and fell as low as -$28.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Jushi Holdings | 80.52 Mn | 40.82 Mn | 29.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8.57 Mn |
| Dec 31, 2023 | 8.57 Mn |
| Dec 31, 2022 | -28.18 Mn |
| Dec 31, 2022 | -28.18 Mn |
| Sep 30, 2022 | 37.60 Mn |
| Sep 30, 2022 | 37.60 Mn |